arGEN-X

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

arGEN-X was founded in 2001 by Prof. Dr Désiré Collen, Dr. Johannes Forssmann and Dr. Ingunn Hokland as a spin-off from the University of Antwerp in Belgium. The company developed from academic research conducted by Prof. Dr Désiré Collen and his team, with the aim of creating novel biologics and other innovative treatments for autoimmune diseases. Since then, the company has grown significantly and established itself as a global leader in the field of antibody therapeutics.

At arGEN-X, our mission is simple: to provide innovative, targeted therapies that make a real difference in the lives of patients with autoimmune disease.

We strive to be a leader in the discovery and development of novel, targeted therapies that provide life-changing benefits to patients with autoimmune diseases.